|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
CTG004761324 |
| 003 |
DE-627 |
| 005 |
20230629100629.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
210507s2023 xx |||||o 00| ||eng c |
| 035 |
|
|
|a (DE-627)CTG004761324
|
| 035 |
|
|
|a (UBBS_Klinische_Studien_WHO)EUCTR2016-001583-11-PL
|
| 035 |
|
|
|a (UBBS_Klinische_Studien_WHO)G1T28-02
|
| 035 |
|
|
|a (UBBS_Klinische_Studien_WHO)2016-001583-11-HU
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 245 |
1 |
0 |
|a A study to assess the safety and tolerability of combining G1T28 with etoposide and carboplatin therapy and to evaluate the effect of G1T28 on blood cell production affected by chemotherapy.
|b Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC) Receiving Etoposide and Carboplatin Chemotherapy - G1T28 safety and pharmacokinetic study in patients receiving etoposide and carboplatin
|
| 264 |
|
1 |
|c 2023
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a Computermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 23-11-2016, Last updated: 2023-06-29
|
| 650 |
|
4 |
|a Medical Condition: Extensive-Stage Small Cell Lung Cancer (SCLC) MedDRA version: 20.0Level: PTClassification code 10041068Term: Small cell lung cancer extensive stageSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps);Therapeutic area: Diseases [C] - Cancer [C04]
|
| 650 |
|
4 |
|a Study Type: Interventional
|
| 650 |
|
4 |
|a Phase: Phase 1
|
| 650 |
|
4 |
|a Recruitment Status: Not yet recruiting
|
| 650 |
|
4 |
|a 610
|
| 773 |
0 |
8 |
|i Enthalten in
|t WHO International Clinical Trials Registry Platform
|g (2023) vom: 21. Juni
|
| 773 |
1 |
8 |
|g year:2023
|g day:21
|g month:06
|
| 856 |
4 |
0 |
|u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-001583-11
|z kostenfrei
|3 Volltext
|
| 912 |
|
|
|a GBV_CTG
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|j 2023
|b 21
|c 06
|
Klinische Studie